Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer

By Agelaki Sofia   Georgoulias Vassilis  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 855-874

Informa Healthcare

Access to resources Recommend Favorite

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

By Lo Peter C.   Dahlberg Suzanne E.   Nishino Mizuki   Johnson Bruce E.   Sequist Lecia V.   Jackman David M.   Jänne Pasi A.   Oxnard Geoffrey R.  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2570-2577

Blackwell Publishing

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer

By Dancey Janet E.  

Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. : 1125-1138

Adis International

Access to resources Recommend Favorite

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 12, Iss. 6, 2011-06 ,pp. : 922-933

Bentham Science Publishers

Access to resources Recommend Favorite